|
| 37676819 | Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. | J Natl Cancer Inst | 2024 |
| 36996325 | Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 37330052 | Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. | Ann Oncol | 2023 |
| 34895867 | Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. | Eur Urol Oncol | 2022 |
| 35507889 | Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. | JCO Precis Oncol | 2022 |
| 35859180 | Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. | Nature | 2022 |
| 35982066 | PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas. | Sci Rep | 2022 |
| 36251389 | The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. | Cancer Res | 2022 |
| 33414135 | <i>BRCA2</i>, <i>ATM</i>, and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. | Clin Cancer Res | 2021 |
| 33836265 | Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. | Ann Oncol | 2021 |
| 34083234 | Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. | Clin Cancer Res | 2021 |
| 33420073 | Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. | Nat Commun | 2021 |
| 32451180 | Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. | Eur Urol | 2020 |
| 32046920 | Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. | Clin Genitourin Cancer | 2020 |
| 31744831 | Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. | Clin Cancer Res | 2020 |
| 31660579 | Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. | Histol Histopathol | 2020 |
| 32574722 | HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. | Ann Oncol | 2020 |
| 32555329 | AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. | Oncogene | 2020 |
| 30638634 | Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. | Eur Urol | 2019 |
| 31727538 | Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. | Lancet Oncol | 2019 |
| 32914020 | Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. | JCO Precis Oncol | 2019 |
| 32923850 | Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. | JCO Precis Oncol | 2019 |
| 31358384 | Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. | Urol Oncol | 2019 |
| 31585777 | Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. | Urol Oncol | 2019 |
| 31056399 | A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. | Clin Genitourin Cancer | 2019 |
| 30665814 | Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. | Eur Urol | 2019 |
| 29367197 | Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. | Cancer Discov | 2018 |
| 29858379 | Erratum: Whole-exome sequencing identifies germline mutation in <i>TP53</i> and <i>ATRX</i> in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. | Cold Spring Harb Mol Case Stud | 2018 |
| 29988112 | Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. | Br J Cancer | 2018 |
| 30015382 | Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. | J Pathol | 2018 |
| 30272002 | Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancer. | Commun Biol | 2018 |
| 29602769 | Whole-exome sequencing identifies germline mutation in <i>TP53</i> and <i>ATRX</i> in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. | Cold Spring Harb Mol Case Stud | 2018 |
| 29762619 | Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. | Lab Chip | 2018 |
| 29563510 | Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. | Nat Commun | 2018 |
| 27324055 | Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. | Clin Genitourin Cancer | 2017 |
| 28259476 | Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. | Eur Urol | 2017 |
| 28407731 | Segmentum: a tool for copy number analysis of cancer genomes. | BMC Bioinformatics | 2017 |
| 28379477 | Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. | Neuro Oncol | 2017 |
| 28450426 | Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. | Cancer Discov | 2017 |
| 28468611 | Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. | BMC Cancer | 2017 |
| 29206995 | Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. | J Natl Cancer Inst | 2017 |
| 29269934 | The expression of AURKA is androgen regulated in castration-resistant prostate cancer. | Sci Rep | 2017 |
| 28842510 | Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. | Clin Cancer Res | 2017 |
| 28760909 | Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. | Clin Cancer Res | 2017 |
| 25893308 | IGFBP2 potentiates nuclear EGFR-STAT3 signaling. | Oncogene | 2016 |
| 27148695 | Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. | JAMA Oncol | 2016 |
| 27148588 | Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. | Cold Spring Harb Mol Case Stud | 2016 |
| 26939004 | Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. | PLoS One | 2016 |
| 26797585 | Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. | Clin Genitourin Cancer | 2016 |
| 25749039 | Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. | Oncotarget | 2015 |